drugset / Trial / NCT00432627
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.
Timeline
- Start
- 2006-12
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | 20 mg/kg | Oral |
Indications
No indication recorded.